Abstract Purpose: Studies herein explore paclitaxel enhancement of the therapeutic efficacy of a-particle-targeted radiation therapy. Experimental Design: Athymic mice bearing 3 day i.p. LS-174T xenografts were treated with 300 or 600 Ag paclitaxel at 24 h before, concurrently, or 24 h after [ 212 Pb]trastuzumab (10 ACi). The 300 Ag paclitaxel 24 h before radioimmunotherapy (RIT) failed to provide benefit, whereas 600 Ag extended the median survival from 44 to 171days. Conclusions:These results suggest that regimens combining chemotherapeutics and high linear energy transfer (LET) RIT may have tremendous potential in the management and treatment of cancer patients. Dose dependency and administration order appear to be critical factors requiring careful investigation.
In the past year in the United States, it was estimated that f37,170 people would be diagnosed with pancreatic adenocarcinoma and f33,370 will die (1). The 5-year relative survival rate is only 5% for all stages of pancreatic cancer. The outlook for patients with ovarian cancer is not appreciably better. In 2007, it was estimated that f22,430 women were diagnosed with ovarian cancer, 67% to 69% of whom presented with distant, metastatic disease. The overall 5-year relative survival rate is 40% to 45%. Over the years, there has been a trend toward improvement in this situation by a few percentage points, although that seems imperceptible in the 5-year relative survival rates for both diseases. Clearly, development of new tactics for the treatment and management of patients with pancreatic or ovarian cancer remains a high priority (1) .
Targeted radiation therapy is one such strategy that has been reinvigorated in recent years with the Food and Drug Administration approval of Zevalin and Bexxar. In fact, numerous preclinical and clinical studies have appeared in the literature that focus on the application of radioimmunotherapy (RIT) as a treatment modality for i.p. disease (2 -9) . The majority of these studies have used monoclonal antibodies (mAb) conjugated with h-emitting radionuclides (e.g., 131 I, 90 Y, and 177 Lu). The strategy followed by this laboratory has been to exploit the superb cytotoxicity of a-particle radiation using a mAb as the targeting vehicle of s.c. and i.p. xenografts (6 -8, 10) . Only three to six transversals of a cell's nucleus by a-particles delivers a dose of 70 to 100 cGy; a-particle radiation is cytotoxic at a dose rate as low as 1 cGy/h (11 -13) . The characteristic short path lengths of a-particles render this radiation ideal for the treatment of small tumor burdens, disseminated disease, and micrometastatic disease and for the elimination of malignant single cells. The short path length is also hypothesized to limit normal tissue toxicity. This laboratory has recently reported on the therapeutic potential of two a-emitting radionuclides, 213 Bi and 212 Pb (the latter as an in vivo generator of 212 Bi), in a peritoneal murine model (6 -8) . The delivery vector in these studies was trastuzumab targeting HER-2. HER-2 is expressed in an array of epithelial tumors: 35% to 45% of all pancreatic adenocarcinomas, 25% to 30% of ovarian cancers, and 4% to 83% of colorectal adenocarcinomas as well as other diseases (14 -16) . A unique advantage of RIT versus monotherapy with trastuzumab is that neither high expression nor homogeneous expression of HER-2 throughout the tumor is required to affect therapy. This laboratory has taken a systematic approach in the development of treatment regimens using either 213 Bi-or 212 Pb-labeled trastuzumab. Trastuzumab with each of the radionuclides was effective in increasing the median survival of mice bearing i.p. tumor xenografts after a single administration and subsequently in a multidosing scheme. In the management of oncology patients, combinations of radiotherapy and chemotherapy are common practice to derive a greater therapeutic response (14, 17 -19) . To improve the results, many preclinical and clinical studies have been conducted to identify more effective cytotoxic agents or radiosensitizers and combinations thereof. Within this context, studies in this laboratory have been extended to explore whether high linear energy transfer (LET) radiation therapy could be potentiated by incorporating chemotherapeutics into the regimen. Gemcitabine was the first chemotherapeutic drug that was evaluated in conjunction with [
212 Pb]trastuzumab (7) . In the study, it was shown that therapeutic responses were greatly improved in a one-or two-cycle regimen.
Paclitaxel (Taxol) is another chemotherapeutic under intense scrutiny. Paclitaxel stabilizes microtubule formation, which results in cells being arrested in the G 2 -M phase of the cell cycle, causes BCL2 dysfunction, and activates apoptosis (20 -22) . Paclitaxel has activity against ovarian and pancreatic cancer and is a recognized radiosensitizer, which has been reported to sensitize ovarian and pancreatic cancer cells/tumors to the cytotoxic effects of radiation (23 -25) . The drug has been evaluated in combination with radiotherapy and radiolabeled antibodies in animal models and in patients and has been shown to provide additional therapeutic benefit (9, 26 -31) .
The mechanism of action by paclitaxel distinctly differs from that of gemcitabine and as such would add another class of chemotherapeutics to the armamentarium to be combined with radiolabeled antibodies. The studies described herein are an evaluation of the ability of paclitaxel to potentiate the therapeutic efficacy of HER-2 targeting a-emitting high-LET 213 Bi-and 212 Pb-labeled trastuzumab in a multimodality regimen for the management of disseminated i.p. disease.
Materials and Methods
Cell lines. All therapy studies were conducted using the LS-174T, a human colon carcinoma cell line. SKOV-3, a human ovarian carcinoma cell line that expresses f1 Â 10 6 HER-2 molecules per cell, was used for in vitro analysis (32) . LS-174T was grown in supplemented DMEM as described previously (33) . SKOV-3 cells were maintained in McCoy's 5a medium supplemented with 10% fetal bovine serum and 1 mmol/L nonessential amino acids. Media and supplements were obtained from Quality Biologicals, Invitrogen, or Lonza.
Chelate synthesis and mAb conjugation. The synthesis, characterization, and purification of the bifunctional ligands, TCMC and CHX-A 00 -DTPA, have been described previously (34, 35) . Conjugation of trastuzumab with either CHX-A 00 -DTPA or TCMC has been described previously (34, 35) . The final concentration of trastuzumab was quantified by the method of Lowry (36) . The number of CHX-A 00 -DTPA or TCMC molecules linked to the mAb was determined using spectrophotometric assays based on the titration of either yttrium or lead-Arsenazo (III) complex, respectively (37, 38) .
Radiolabeling. A 5 to 10 mCi 224 Ra/
212
Pb generator (AlphaMed) was washed with 2 mol/L HCl (3 mL) to remove impurities, unbound 224 Ra, daughter isotopes, and any damaged resin or organic residue. On the following day, 212 Pb was eluted from the generator with 1 mol/L HCl (3 mL). The eluate was heated to dryness; the residue was dissolved in 0.1 mol/L HNO 3 (2 Â 0.2 mL) and used for radiolabeling of mAb as detailed elsewhere (8) . The radiolabeled mAb was purified using a desalting column (PD-10; GE Healthcare) with PBS as the eluant. HuIgG (ICN) was similarly conjugated with TCMC and radiolabeled with 212 Pb as described above to serve as a negative control in these studies. A calibrated Ge(Li) detector (model GEM10185-P; EG&G Ortec) coupled to a multichannel analyzer Gamma Vision version 5.2 software (EG&G Ortec) was used for radioactivity measurements. 212 Pb activity was determined by measurement of the 238.6 keV g-ray (43.6%).
213
Bi was obtained from a 225 Ac/ 213 Bi generator (Oak Ridge National Laboratories or Actinium Pharmaceuticals). Elution of the 213 Bi and radiolabeling of trastuzumab-CHX-A'' was done as described previously (10) .
Radioimmunoassay. Immunoreactivities of the radiolabeled preparations were assessed in a radioimmunoassay using methanol-fixed cells. Briefly, SKOV-3 cells were trypsinized, pelleted, and resuspended in PBS (pH 7.2) containing 1% bovine serum albumin. Serial dilutions of radiolabeled trastuzumab (f140 to 8 nCi) were added in duplicate to cells (1 Â 10 6 ) in 50 AL of 1% bovine serum albumin in PBS. The cells were washed with 4 mL of 1% bovine serum albumin in PBS following a 2 h ( 213 Bi) or 18 h ( 212 Pb) incubation at room temperature, pelleted at 1,000 Â g for 5 min, and the supernatant was decanted. The
Translational Relevance
These investigations reported herein show the potential of combining chemotherapeutics with high-LET RIT for the management and treatment of cancer patients who present with disseminated peritoneal disease at the time of their diagnosis. These studies are a natural progression to prior studies that established the efficacy of paclitaxel administered in conjunction with h-radiation RIT for the treatment of ovarian patients. Chemotherapy in conjunction with a-particle RITusing the appropriate targeting vehicle would be an effective adjuvant therapy following procedures such as cytoreductive surgery or peritoneal external beam radiation therapy. The intent of developing a treatment regimen using a-targeted radiation is to expand the repertoire to patient populations. Such a strategy would be potentially beneficial for not only those with pancreatic or ovarian cancer but also those with cancers of the colon, stomach, and small intestine, which result in peritoneal carcinomatosis as well as those with peritoneal mesothelioma. In general, the results obtained define a potentiating interaction between paclitaxel and the high-LET a-radiation-labeled trastuzumab. The studies also illustrate the necessity of establishing the optimal administration sequence of the treatment components and that dose dependency and administration order are critical factors that require careful investigation.
212
Pb was detected using the Ge(Li) detector, whereas the 213 Bi was measured in a g-counter (WizardOne; Perkin-Elmer). The binding percentage was calculated for each dilution. The specificity of the radiolabeled trastuzumab was confirmed by incubating one set of cells with f200,000 counts/min of radiolabeled trastuzumab with an excess (5 Ag) of unlabeled trastuzumab.
Therapy studies. Therapy studies were done using 19 to 21 g female athymic (nu/nu) mice (Charles River Laboratories). The mice were injected i.p. with 1 Â 10 8 cells LS-174T in 1 mL medium or PBS as reported previously (39) . Radiolabeled trastuzumab, 500 ACi 213 Bi] and [ 212 Pb]trastuzumab, respectively, is based on previous studies that determined these doses were the lower range of the maximum effective therapeutic dose (10, 11, 16) . When combining a-particle RIT with chemotherapeutics, it was considered that alterations in tumor sensitivity to radiation would be more discernible if the lower effective doses of [ 213 Bi] or [ 212 Pb]trastuzumab were administered and that any incipient toxicity that might be incurred by doing these studies at higher doses would not obscure observation of enhanced therapy.
In study 1, mice (n = 9-10) with 2 days i.p. LS-174T xenografts were injected (i.p.) with 300 or 600 Ag paclitaxel. On the following day (24) (25) (26) (27) (28) (29) (30) Bi RIT. In this experiment, mice (n = 10) received an i.p. injection of paclitaxel (300 or 600 Ag) concurrently or 24 to 30 h after the 213 Bi RIT. Control groups were the same as outlined in study 1.
In study 3, multiple doses of paclitaxel (600 Ag/wk for up to 3 weeks) were given to mice (n = 8-10) bearing LS-174T i. Progression of disease, especially during the first weeks of the experiment, was observed as an extension of the abdomen, development of ascites, and with noticeable, palpable nodules in the abdomen. Weight loss would occur as an acute response following treatment or much later as the experiments progressed. Mice were monitored and euthanized if found to be in distress, moribund, or cachectic. Mice were also euthanized when 10% to 20% weight loss occurred or if bloating or tumor nodules were apparent. All animal protocols were approved by the National Cancer Institute Animal Care and Use Committee.
Statistical Bi]trastuzumab and survival (time to sacrifice or natural death). Groups were compared using a log-rank test. A dose-response relationship was examined by treating the dose level as a linear covariate in the Cox model and tested whether the corresponding regression variable was zero using a likelihood ratio test.
For the animal weight data, the maximum percent reduction from baseline was estimated for each mouse. This was calculated as the ratio of the maximum reduction in weight from baseline during the initial 4-week period divided by the baseline weight of the mouse. Box plots were constructed for each treatment group that show the median, upper, and lower quartiles as well as identifying outliers. Differences between treatment groups were tested using a Kruskal-Walis test (nonparametric ANOVA) for comparison of multiple groups and the Wilcoxon rank-sum test was applied when comparing two groups. All reported P values correspond to two-sided tests.
Results
Previous studies from this laboratory showed potentiation of high-LET radiation ([ 212 Pb]trastuzumab) by gemcitabine (7). Induction of G 2 arrest via microtubule stabilization by paclitaxel provides for an alternate strategy for enhancing the therapeutic response to a-particle radiation. The first study exploring the combination of paclitaxel with high-LET radiation was done with [
213 Bi]trastuzumab in the LS-174T i.p. model (6 -8) . Athymic mice (n = 10) bearing a 2-day tumor burden were treated i.p. with either 300 or 600 Bi]HuIgG had a median survival of 25 days compared with 19 days for the untreated group (P = 0.09). The median survival for the mice that were injected with the paclitaxel alone was 31 days for the 300 Ag dose and 43 days for the 600 Ag dose. In those animals given the combination, no further improvement in the median survival was observed at either 300 Ag (42 days) or 600 Ag (46 days) dose of paclitaxel (P = 0.84). The two groups that were injected with 300 and 600 Ag paclitaxel followed by treatment the next day with [ 213 Bi]HuIgG had a median survival of 42 versus 25 days for the group that received [ 213 Bi]HuIgG alone. The increase from 25 to 42 days observed in these groups was found to be statistically insignificant (P = 0.07).
Based on these results, the timing of the paclitaxel administration was reexamined and a study was conducted in Fig. 1A -C, respectively) The weights of the mice were recorded over a 4-week period monitoring the potential toxicity of the treatment regimens. Some weight loss was observed among the various groups in this particular RIT study (Fig. 2) . The differences were significant among the groups that were untreated or injected with [ The potential of combining [ 212 Pb]RIT with paclitaxel was also investigated. A therapy study was again conducted in 212 Pb-labeled antibodies alone, at each of the paclitaxel doses alone, and one group was left untreated. Consistent with prior studies (Table 3) , a modest but significant therapeutic effect due to the paclitaxel alone was observed. Median survival of the untreated group was 16 days, whereas for those receiving either 300 or 600 Ag paclitaxel this was extended to 31 and 29 days, respectively (P = 0.007). The 300 Ag dose of paclitaxel appears to only have a modest affect on median survival irrespective of the timing of the administration of the [ A box plot showing the distribution of maximum percent reduction in weight over follow-up across the 17 groups is given in Fig. 3 . Toxicity was low in 13 of the groups. Changes in weight were observed in those groups that were injected with paclitaxel, at either 300 or 600 Ag dose, 24 h after the 212 Pb RIT was administered. A comparison of paclitaxel after [ 212 Pb]trastuzumab with trastuzumab alone showed a statistically significant increase in toxicity with paclitaxel at the 300 Ag dose (P = 0.05). There is a statistical trend of an increase for the 600 Ag dose (P = 0.10). Similar differences for HuIgG were also noted with a statistically significant increase in toxicity at the 600 Ag paclitaxel 24 h after [ 
Discussion
Food and Drug Administration approval of ''naked'' mAbs such as trastuzumab (Herceptin), cetuximab (Erbitux), and panitumumab (Vectibix) and of the radiolabeled mAbs, Zevalin and Bexxar, are ample evidence of the burgeoning interest and ongoing efforts to incorporate mAbs into cancer patient treatments. The strategy of molecular targeting, in conjunction with the realization that treatments will likely be tailored to individual patients, provides the impetus for development and refinement of mAb-based therapies.
The efficacy of targeted a-particle radiation has been shown with increasing frequency in both preclinical and clinical settings (2, 5 -8) . As hypothesized, targeted a-particle radiation is effective in the treatment of low disease burden, especially when administered locoregionally or when applied for Bi RITon animal weight. The maximum percent reduction in weight was calculated for each of the treatment groups and presented as box plots. Light line, median; top region, third quartile; bottom region, first quartile; brackets, 1.5 times the interquartile range; lines outside of the brackets, outlying observations. Alterations in the weights of the mice during and 4 wk following treatment were monitored as an indicator of toxicity. treatment of single-cell disease. There remains, however, a great deal to improve upon with this therapeutic mode.
As with other modalities, expectations with RIT are that this would not be a stand-alone treatment but would become incorporated as an element of a multimodality treatment scheme. Chemotherapeutics (e.g., gemcitabine, paclitaxel, cisplatin, 5-fluoruracil, and doxorubicin) in combination with RIT are under evaluation (7, 9, 22, 26 -29, 40 -42) . This laboratory has recently reported on the potentiation of high-LET radiation using gemcitabine in combination with [ 212 Pb]trastuzumab targeting HER-2 (7, 8) . Paclitaxel as the next chemotherapeutic for investigation was an attractive candidate based on several factors including established usage and radiosensitization properties. The studies reported here were designed to explore conditions for the i.p. administration of paclitaxel with a-particle RIT with the objective of developing a multicycle treatment scheme for both 213 Bi and 212 Pb RIT. In the design of the experiments, it was felt that i.p. administration of the paclitaxel would result a higher local concentration of the paclitaxel being achieved. The adsorption rate of paclitaxel from the peritoneum into the peripheral circulation is slow, which in turn prolongs the exposure of tumor to the drug and minimizes systemic exposure and resultant toxicities (43, 44) . Paclitaxel given by i.p. administration, particularly in combination with RIT, is not unprecedented. Ovarian cancer patients tolerated 177 Lu RIT in combination with paclitaxel and IFN with only a transient neutropenia noted 2 to 3 weeks after the paclitaxel administration (9) . Similar findings were observed in ovarian cancer patients receiving paclitaxel, IFN, and 90 Y-CC49 (9). Pb ]trastuzumab used in these experiments had been determined to be the lower range of the maximum effective therapeutic dose for each radioimmunoconjugate (6 -8, 14) . The decision to use these doses in subsequent experiments was based on the reasoning that the lower effective dose ranges were less likely to mask alterations in sensitivity conferred by other modalities such as chemotherapeutics during combination therapy.
The first study evaluating paclitaxel with targeted a-particle was conducted with trastuzumab radiolabeled with 213 Bi. Based on the 46 min half-life of the radionuclide, administration of paclitaxel to the mice was executed 24 h before administration of [
213 Bi]trastuzumab. Paclitaxel has been shown to persist in the peritoneal cavity (t 1/2 = 73 F 18 h), which would allow time for radiosensitization to occur (44) Bi]trastuzumab. Consistent with the literature, the greatest therapeutic response was obtained when 600 Ag paclitaxel was given f24 h after RIT, with a therapeutic index of 9 being realized. It should be noted that a therapeutic index of 6.2 was also obtained for the group of animals that were treated with 300 Ag paclitaxel given with the [
213 Bi]trastuzumab. At the time of designing this first study, there were two areas of experience to draw upon in the literature. One was the combination of paclitaxel with conventional external beam radiotherapy. Paclitaxel had been shown to enhance in vivo the radiation response of murine mammary carcinoma to radiotherapy when given up to 24 h before radiotherapy (45) . The combination of paclitaxel and radiotherapy resulted in an increase in mitotically arrested tumor cells and with a corresponding increase in apoptosis. In vitro RIT studies by Supiot et al. showed that paclitaxel added to three different multiple myeloma cell lines 24 h before 213 Bi RIT using mAb B-B4 resulted in a decrease in survival in all three cell lines (22) . When examined further, the investigators found that only one of the cell lines responded to the combined treatment with a modest increase in apoptosis. In these same studies, the potential of doxorubicin was also evaluated for its ability to sensitize cells to targeted a-particle radiation. In this case, doxorubicin not only inhibited cell growth but also was found to increase the amount of DNA strand breaks and frequency of apoptosis. The first RIT study combining paclitaxel with 90 Y-ChL6 therapy from DeNardo et al. showed potentiation of therapy by paclitaxel (29) . Scheduling of paclitaxel with the RIT was examined and was found to affect a response rate of 100% when started 24 h before RIT. The greatest number of cures, however, was obtained when paclitaxel was administered 24 h after the 90 Y-ChL6 (29 low-LET radiation as opposed to the high-LET radiation associated with a-emitters.
Because (26, 29) . In the original study, a 100% response rate and responses that included partial and complete regression with cures were reported when paclitaxel was given before the RIT (29) . Paclitaxel (600 Ag) given 24 h after RIT generated the highest number of cures (29) . Clearly, empirical studies evaluating the scheduling of a chemotherapeutic with RIT is warranted. As shown by the studies described here, the sequence of administration is directly dependent on the radionuclide being targeted. One probably should not be surprised then to discover that the administration sequence might also be dependent on the targeting vehicle and the target as well.
With the objective of developing a multicycle chemo-RIT treatment regimen, studies were done assessing a single injection of [
213 Bi]trastuzumab with paclitaxel being given up to three times at 1-week intervals. Paclitaxel was found to potentiate the therapeutic effectiveness of [
213 Bi]trastuzumab with the greatest benefit being derived from two doses of paclitaxel given after the RIT. To date, one other study has reported results of administering multiple doses of paclitaxel with RIT (28) . In this particular study, 300 Ag paclitaxel was administered 48 and 72 h after 90 Y RIT with two different mAb, one targeting carcinoembyronic antigen (T84.66) and the other targeting HER-2 (trastuzumab). The fractionated paclitaxel dose was found to be effective in inhibiting tumor growth; however, the investigators did not include a direct comparison with a single dose of paclitaxel, nor did they include a nonspecific mAb making it challenging to objectively deconvolve their results versus the therapeutic components.
The overall objective of these studies was to investigate the conditions for a treatment regimen that incorporated a-particle RIT with a chemotherapeutic. Paclitaxel was chosen due to its (a) reported radiosensitization properties, (b) reported synergism with trastuzumab, and (c) proven effectiveness in treating pancreatic cancer patients (6, 47, 48) . Interestingly, the LS-174T xenografts used in these studies are modestly responsive to paclitaxel with increases in the therapeutic index ranging from 1.5 to 2. To understand how paclitaxel enhances the therapeutic response to RIT, a study was conducted by Miers et al. to answer whether there is an effect on the cumulative activity in the tumor. The authors compared patients receiving 90 Y-RIT (m170) with (n = 5) and without (n = 7) paclitaxel (49) . When patients were given paclitaxel 2 days after the RIT, an increase in the cumulated tumor activity was observed. No differences were observed in normal tissue. Similar results were obtained when mice bearing breast cancer xenografts were injected with 111 In-DOTA-Gly3-Phe-ChL6 and then treated with paclitaxel 24 h later (49) . Similar studies are planned to test whether the same phenomenon occurs with the LS-174T i.p. xenograft model following paclitaxel therapy.
These investigations suggest that regimens combining chemotherapeutics and high-LET RIT may have tremendous potential in the management and treatment of pancreatic and ovarian cancer patients who present with peritoneal disease at the time of diagnosis. This treatment regimen may also prove beneficial to other patient populations with cancers, such as the colon, stomach, and small intestine, which result in peritoneal carcinomatosis as well as those with peritoneal mesothelioma (50) .
Chemotherapy in conjunction with a-particle RIT using the appropriate targeting vehicle would be an effective adjuvant therapy following procedures such as cytoreductive surgery or peritoneal external beam radiation therapy. Although some of the observed effects are difficult to explain and warrant further study, on the whole, the general results obtained point in the direction of a potentiating interaction between paclitaxel and the high-LET a-radiation-labeled trastuzumab. The studies also illustrate the necessity of establishing the optimal administration sequence of the treatment components and that dose dependency and administration order are critical factors that require careful investigation.
